Biocept Overview

  • Founded
  • 1997
Founded
  • Status
  • Public
  • Employees
  • 134
Employees
  • Stock Symbol
  • BIOC
Stock Symbol
  • Share Price
  • $4.05
  • (As of Thursday Closing)

Biocept General Information

Description

Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.

Contact Information

Website
www.biocept.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Laboratory Services (Healthcare)
Stock Exchange
NAS
Primary Office
  • 5810 Nancy Ridge Drive
  • Suite 150
  • San Diego, CA 92121
  • United States
+1 (858) 000-0000

Biocept Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Biocept Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.05 $4.02 $3.26 - $8.38 $59.2M 14.7M 1.08M -$0.23

Biocept Financials Summary

In Thousands,
USD
TTM 30-Jun-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 54,753 45,328 8,669 (3,875)
Revenue 54,901 27,461 5,529 3,250
EBITDA 117 (16,569) (24,115) (23,458)
Net Income (2,204) (17,807) (25,138) (24,572)
Total Assets 50,603 47,452 17,733 8,750
Total Debt 13,135 12,229 2,540 1,627
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Biocept Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Biocept‘s full profile, request access.

Request a free trial

Biocept Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable i
Laboratory Services (Healthcare)
San Diego, CA
134 As of 2020
00000
000000000 00000

00000000

iusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exe
0000000000 000000000
Boulder, CO
000 As of 0000
00000
0000 0000-00-00
00000000 00000

00000000

fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia de
0000000000 00000000 (0000000000)
Waltham, MA
00 As of 0000
0000
00000000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Biocept Competitors (20)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Biodesix Formerly VC-backed Boulder, CO 000 00000 00000000 00000
00000000 00000000 Venture Capital-Backed Waltham, MA 00 0000 00000000000 0000
00000000000 Venture Capital-Backed Birmingham, AL 00 00.000 0000000000 0 00.000
000000 Formerly VC-backed Vista, CA 000 00000 00000000 00000
00000000 000000000 Venture Capital-Backed Wuxi, China 00000 00000000000 00000
You’re viewing 5 of 20 competitors. Get the full list »

Biocept Patents

Biocept Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2012250516-B2 Methods for detecting nucleic acid sequence variants Active 04-May-2011 0000000000 0
US-20200340052-A1 Methods for detecting nucleic acid sequence variants Pending 04-May-2011 0000000000
US-20180112263-A1 Methods for detecting nucleic acid sequence variants Granted 04-May-2011 0000000000
US-10745749-B2 Methods for detecting nucleic acid sequence variants Active 04-May-2011 0000000000 00
US-20140335514-A1 Methods for detecting nucleic acid sequence variants Granted 04-May-2011 C12Q1/6844 0

Biocept Executive Team (19)

Name Title Board Seat Contact Info
Michael Nall Chief Executive Officer & Board Member
Timothy Kennedy Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Lyle Arnold Ph.D Chief Scientific Officer & Senior Vice President
Hendrick Edwin Executive & Senior Vice President
Michael Dugan Chief Medical Officer, Senior Vice President & Director
You’re viewing 5 of 19 executive team members. Get the full list »

Biocept Board Members (17)

Name Representing Role Since
Bruce Gerhardt Self Board Member 000 0000
David Hale Self Chairman of the Board 000 0000
Faye Wilson Biocept Chair of Audit Committee & Board Member 000 0000
Ivor Royston MD Self Board Member 000 0000
Marsha Chandler Ph.D Self Board Member 000 0000
You’re viewing 5 of 17 board members. Get the full list »

Biocept Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Biocept Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Biocept‘s full profile, request access.

Request a free trial